NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

FABINO ENTERPRISES

BSE: 543444 21 Feb 2025
Healthcare
₹ 27.4
Fabino Life Sciences Limited is a company operating in the Healthcare sector, focusing on core business activities related to its industry.

FABINO ENTERPRISES - Share Price & Details

Market Cap
₹5.75
High /Low
39.6 / 23.6
Stock P/E
115.0
Book Value
₹20.0
Dividend Yield
0.0
ROCE
1.68
ROE
₹1.21
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹36.5
Debt
1.21
CMP / FCF
-5.36
Debt to equity
₹0.29
NP Ann
0.05
High price all time
49.0
Piotroski score
₹4.0
Graham Number
10.4
No. Eq. Shares
0.21
Net CF
₹-0.22
Net profit
0.05
Price to book value
1.37
Interest Coverage
₹2.0
Low price all time
22.5
Industry PE
28.9
Reserves
₹2.10
Free Cash Flow
₹-0.58

Price Chart


Volume Chart


Peer Comparison

Stock Net Sales EPS P/E
Shyama Computronics and Servic0.61NA30.9
Triochem Products Ltd.,NA3.60
FABINO ENTERPRISES LIMITEDNANA115.0
Shyama Computronics and Servic0.61NA30.9
Triochem Products Ltd.,NA3.60

Peer Comparison Chart


About FABINO ENTERPRISES

Fabino Life Sciences Limited has established itself in the Healthcare sector, offering a range of products and services that cater to its market. With a strong presence in its field, the company is committed to growth and innovation in the industry.


Latest News

Fabino Enterprises Limited Reports Earnings Results for the Half Year Ended September 30, 2024

(10 Jan 2025)
Fabino Enterprises Limited reported earnings results for the half year ended September 30, 2024. For the half year, the company reported sales was INR 42.51...
Read more →

Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Octreotide

(20 Nov 2024)
Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European...
Read more →

7 Levels Of Wealth: What Stage Are You At In 2024 According To Grant Sabatier?

(26 Sep 2024)
In a world where financial anxieties loom, many Americans wonder just how financially secure they are.For those wondering, Grant Sabatier,...
Read more →

Zydus Lifesciences Ltd receives warning letter from USFDA for Jarod injectables manufacturing facility

(13 Sep 2024)
Zydus Lifesciences Ltd has received a Warning Letter issued by the USFDA relating to its Injectables manufacturing facility at Jarod near...
Read more →

USFDA completes inspection at transdermal manufacturing site of Zydus Lifesciences Ltd

(05 Aug 2024)
The USFDA conducted an inspection at the group's transdermal manufacturing site located at SEZ in Ahmedabad.
Read more →

Pinnacle Life Science Pvt Ltd receives EIR from USFDA for Baddi facility

(03 Aug 2024)
US FDA had successfully conducted an inspection at manufacturing facility of Aarti Drugs Ltd's subsidiary, Pinnacle Life Science Private...
Read more →